Exploring metabolic vulnerability and therapeutic potential in cancers with isocitrate dehydrogenase mutations
<p>Treatment of mutant isocitrate dehydrogenase 1 (IDH1) glioma remains challenging; targeted allosteric inhibitors currently provide limited clinical effect. Resistance to mutIDH1 inhibitors has also emerged in other cancers with mutant <em>IDH1</em>. IDH1 catalyses the decarboxyl...
| Glavni autor: | |
|---|---|
| Daljnji autori: | |
| Format: | Disertacija |
| Jezik: | Englihs |
| Izdano: |
2022
|
| Teme: |